在有和无糖尿病的成人中进行的III期试验中，恩格列净符合降低心血管死亡或因心力衰竭住院风险的主要终点
在有和无糖尿病的成人中进行的III期试验中，恩格列净符合降低心血管死亡或因心力衰竭住院风险的主要终点
Search
EMPRISE现实世界研究的中期分析显示，与DPP-4抑制剂和GLP-1受体激动剂相比，恩格列净降低因心力衰竭住院的风险
EMPRISE现实世界研究的中期分析显示，与DPP-4抑制剂和GLP-1受体激动剂相比，恩格列净降低因心力衰竭住院的风险
Knowing the enemy
Knowing the enemy
7 facts you should know about Ileitis
7 facts you should know about Ileitis
From prevention to prediction
从预防到预测
Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030
Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030
World Water Day - Making every drop count
World Water Day - Making every drop count
Spotlight On Poultry
Spotlight On Poultry
Global poultry trends: A quick-fire look
Global poultry trends: A quick-fire look
Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements
Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements
Boehringer Ingelheim increases commitments to sustainable development, to impact 50 million people through social innovation
Boehringer Ingelheim increases commitments to sustainable development, to impact 50 million people through social innovation
A Unique Bond: human and animal health
Boehringer Ingelheim opens Health Management Centre in China
Boehringer Ingelheim opens Health Management Centre in China
404 Not Found
404 Page
Ethics and Compliance
Ethics and Compliance
Our Global Support Program
Our Global Support Program
Protecting Animals and Humans
Protecting Animals and Humans
Science and Innovation - Human Health Innovation
Science and Innovation - Human Health Innovation
Press Material
Find the latest press releases from Boehringer Ingelheim on animal health or access our media pool to view BI corporate news.
Contact Us
Contact Us
Press Releases
Find the latest press releases from Boehringer Ingelheim on animal health, prescription medicine, pipeline and corporate news.
Healthcare professionals
新冠肺炎 - 医疗保健专业人士
Stop of treatment in COVID-19 study
Stop of treatment in COVID-19 study
SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
Developing potential treatment for severe COVID19 complications
Developing potential treatment for severe COVID19 complications